<DOC>
	<DOCNO>NCT00000717</DOCNO>
	<brief_summary>To determine safety effectiveness clindamycin primaquine treatment mild Pneumocystis carinii pneumonia ( PCP ) AIDS patient . As many 80 percent AIDS patient experience least one episode PCP one-third patient recurrence disease . Drugs currently use treatment acute PCP toxic majority AIDS patient . The combination clindamycin primaquine reduce number PCP organisms laboratory test animal study . Both drug give orally , concentrate lung tissue , use safely humans treatment disease . It possible combination may prove good good standard therapy PCP side effect may less .</brief_summary>
	<brief_title>The Safety Efficacy Clindamycin Primaquine Treatment Mild - Moderate Pneumocystis Carinii Pneumonia Patients With AIDS</brief_title>
	<detailed_description>As many 80 percent AIDS patient experience least one episode PCP one-third patient recurrence disease . Drugs currently use treatment acute PCP toxic majority AIDS patient . The combination clindamycin primaquine reduce number PCP organisms laboratory test animal study . Both drug give orally , concentrate lung tissue , use safely humans treatment disease . It possible combination may prove good good standard therapy PCP side effect may less . The proposal first 20 patient enrol ACTG 044 initially call open-labelled , pilot study intravenous ( IV ) clindamycin primaquine therapy patient mild moderate PCP . Preliminary result first 22 patient enter ACTG 044 indicate response rate therapy 90 percent . The rate discontinuation secondary toxic side effect 20 percent . Additional uncontrolled study show excellent clinical response safety profile another 60 patient . The protocol amend provide oral dose regimen . An additional 20 patient mild PCP enrol tested oral clindamycin primaquine outpatient basis . All patient receive clindamycin primaquine . Total duration therapy 21 day . Patients may hospitalize time study clinically indicate . Treatment zidovudine may start resume completion clindamycin / primaquine therapy . AMENDED : An additional 30 patient instead 20 patient mild PCP enrol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Oral antiemetic . Patients must follow inclusion : HIV positive ELISA , p24 antigen culture . Pneumocystis carinii pneumonia ( PCP ) . Patients must ( Aa ) DO2 &lt; 40 mmHg room air . Willingness sign inform consent . Prior Medication : Allowed : Prophylaxis Pneumocystis carinii pneumonia ( PCP ) agent clindamycin primaquine . Exclusion Criteria Concurrent Medication : Excluded : Hematotoxic therapy , include zidovudine ( AZT ) ganciclovir . Patients follow excluded : History allergy clindamycin , lincomycin , related drug ; primaquine relate drug . Positive screen G6PD deficiency , know NAD methemoglobin reductase deficiency , and/or know hemoglobin M abnormality . Concomitant condition define Patient Exclusion CoExisting Conditions . Any medical social situation , opinion investigator , would adversely affect participation study . Note : Patients may enrol G6PD screen pending , must withdraw result know within 5 day entry . Prior Medication : Excluded within 14 day study entry : Systemic steroid dos exceed physiologic replacement investigational agent . Excluded within 6 week study entry : Prior institution antiprotozoal therapy current episode Pneumocystis carinii pneumonia prophylaxis . Patients must follow symptoms disease : History allergy clindamycin , lincomycin , related drug ; primaquine relate drug . Positive screen G6PD deficiency , know NAD methemoglobin reductase deficiency , and/or know hemoglobin M abnormality . Diarrhea , define = &gt; 3 watery stool per day . Severe nausea vomit medical condition , ileus , preclude oral therapy . Ventilator dependence ( Aa ) DO2 = &gt; 30 mm Hg . Any medical social situation , opinion investigator , would adversely affect participation study . Note : Patients may enrol G6PD screen pending , must withdraw result know within 5 day entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clindamycin</keyword>
</DOC>